{
  "pmid": "41552704",
  "title": "Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial.",
  "abstract": "",
  "pub_date": "2025-10-09",
  "publication_types": [
    "Journal Article"
  ],
  "affiliations": [
    "Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.",
    "Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.",
    "Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.",
    "Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.",
    "Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.",
    "Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.",
    "Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.",
    "Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.",
    "Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."
  ],
  "url": "https://pubmed.ncbi.nlm.nih.gov/41552704/",
  "snapshot_id": "2026-02-12T15-09-21Z",
  "ingested_at": "2026-02-12T15:09:25.497525+00:00"
}